secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-05-19T12:03:26+00:00
Accession:  0001493152-26-024353
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech increases stockholder equity to $2.1M, extends note maturity to June 2027
--------------------------------------------------------------------------------

- Stockholder equity rose to ~$2.1M as of March 31, 2026, from a deficit of ~$9.8M at Dec 31, 2025 (+$11.9M).
- Entered Amendment #2 with Streeterville Capital, extending promissory note maturity to June 30, 2027; outstanding balance ~$1.68M.
- Extension fee of $10,000 added to note balance; additional equity-generating funds raised since March 31.
- CEO states amendment enhances capital allocation flexibility for pancreatic cancer program and other initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226024353/0001493152-26-024353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226024353/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer